MK-927: a topically effective carbonic anhydrase inhibitor in patients

• Published in: Archives of ophthalmology (1960) Vol. 107; no. 8; p. 1143
• Main Authors: Bron, A M, Lippa, E A, Hofmann, H M, Feicht, B I, Royer, J G, Brunner-Ferber, F L, Panebianco, D L, Von Denffer, H A
• Format: Journal Article
• Language: English
• Published: United States 01.08.1989
• Subjects: Adult; Aged; Aged, 80 and over; Carbonic Anhydrase Inhibitors - administration & dosage; Carbonic Anhydrase Inhibitors - therapeutic use; Clinical Trials as Topic; Double-Blind Method; Eye Color; Female; Glaucoma, Open-Angle - drug therapy; Humans; Intraocular Pressure - drug effects; Male; Middle Aged; Ocular Hypertension - drug therapy; Ophthalmic Solutions; Placebos; Random Allocation; Sulfonamides - administration & dosage; Sulfonamides - therapeutic use; Thiophenes - administration & dosage; Thiophenes - therapeutic use
• ISSN: 0003-9950
• DOI: 10.1001/archopht.1989.01070020209026

The effects on intraocular pressure of the novel topical carbonic anhydrase inhibitor MK-927 were investigated for the first time in patients. Three drops of 2% MK-927 was administered in a two-center, double-masked, randomized, placebo-controlled, two-period crossover study in 25 patients with bilateral primary open angle glaucoma or ocular hypertension. At 4.5 hours after the dose, MK-927-treated eyes demonstrated a peak mean change of -7.7 mm Hg from a mean intraocular pressure of 27.8 mm Hg immediately before the dose; this compares with a change of -3.9 mm Hg from a mean intraocular pressure of 28.2 mm Hg when the same eyes were treated with placebo. The peak mean percent change in intraocular pressure in eyes treated with MK-927 was -26.7% at 6 hours after the dose compared with a change of -13.7% after treatment with placebo. No contralateral effect on intraocular pressure due to MK-927 was observed.